NCT01888302View on ClinicalTrials.gov

Sirolimus, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients At High Risk for Cholangiocarcinoma Recurrence After Liver Transplant or Surgery

PHASE1CompletedINTERVENTIONAL
Enrollment

1

Participants

Timeline

Start Date

September 30, 2013

Primary Completion Date

June 30, 2016

Study Completion Date

June 30, 2016

Conditions
Hepatic Complication
Interventions
DRUG

Cisplatin

Given IV

DRUG

Gemcitabine Hydrochloride

Given IV

OTHER

Quality-of-Life Assessment

Ancillary studies

DRUG

Sirolimus

Given PO

Trial Locations (1)

55905

Mayo Clinic, Rochester

Sponsors

Lead Sponsor

Mayo Clinic
All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Mayo Clinic

OTHER